Neurocrine Biosciences ( NASDAQ:NBIX – Free Report ) had its price objective increased by Canaccord Genuity Group from $130.00 to $132.00 in a research report report published on Wednesday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock. Several other analysts have also issued reports on NBIX. UBS Group cut their target price on Neurocrine Biosciences from $137.00 to $125.00 and set a buy rating for the company in a research note on Tuesday, April 4th. SVB Securities raised shares of Neurocrine Biosciences from a market perform rating to an outperform rating and increased their target price for the company from $115.

https://www.dailypolitical.com/2023/08/03/neurocrine-biosciences-nasdaqnbix-given-new-132-00-price-target-at-canaccord-genuity-group.html

#dailypolitical